NOVONESIS (NOVOZYMES) B (NZM2.DE) Fundamental Analysis & Valuation

FRA:NZM2 • DK0060336014

Current stock price

50.86 EUR
+0.89 (+1.78%)
Last:

This NZM2.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. NZM2.DE Profitability Analysis

1.1 Basic Checks

  • In the past year NZM2 was profitable.
  • NZM2 had a positive operating cash flow in the past year.
  • In the past 5 years NZM2 has always been profitable.
  • Each year in the past 5 years NZM2 had a positive operating cash flow.
NZM2.DE Yearly Net Income VS EBIT VS OCF VS FCFNZM2.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

1.2 Ratios

  • NZM2 has a Return On Assets of 3.57%. This is comparable to the rest of the industry: NZM2 outperforms 59.42% of its industry peers.
  • NZM2 has a Return On Equity (5.38%) which is comparable to the rest of the industry.
  • Looking at the Return On Invested Capital, with a value of 4.92%, NZM2 is in line with its industry, outperforming 53.62% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for NZM2 is in line with the industry average of 7.16%.
Industry RankSector Rank
ROA 3.57%
ROE 5.38%
ROIC 4.92%
ROA(3y)5.41%
ROA(5y)8.41%
ROE(3y)9.92%
ROE(5y)16.58%
ROIC(3y)8.21%
ROIC(5y)11.27%
NZM2.DE Yearly ROA, ROE, ROICNZM2.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • NZM2's Profit Margin of 14.04% is amongst the best of the industry. NZM2 outperforms 94.20% of its industry peers.
  • In the last couple of years the Profit Margin of NZM2 has declined.
  • The Operating Margin of NZM2 (21.23%) is better than 94.20% of its industry peers.
  • NZM2's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 53.91%, NZM2 belongs to the top of the industry, outperforming 82.61% of the companies in the same industry.
  • NZM2's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.23%
PM (TTM) 14.04%
GM 53.91%
OM growth 3Y-5.01%
OM growth 5Y-3.32%
PM growth 3Y-12.48%
PM growth 5Y-6.99%
GM growth 3Y-0.4%
GM growth 5Y-0.77%
NZM2.DE Yearly Profit, Operating, Gross MarginsNZM2.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. NZM2.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so NZM2 is still creating some value.
  • NZM2 has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NZM2 has been increased compared to 5 years ago.
  • NZM2 has a worse debt/assets ratio than last year.
NZM2.DE Yearly Shares OutstandingNZM2.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
NZM2.DE Yearly Total Debt VS Total AssetsNZM2.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

2.2 Solvency

  • NZM2 has an Altman-Z score of 3.64. This indicates that NZM2 is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of NZM2 (3.64) is better than 73.91% of its industry peers.
  • NZM2 has a debt to FCF ratio of 4.00. This is a neutral value as NZM2 would need 4.00 years to pay back of all of its debts.
  • The Debt to FCF ratio of NZM2 (4.00) is better than 85.51% of its industry peers.
  • NZM2 has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • NZM2 has a Debt to Equity ratio of 0.12. This is in the better half of the industry: NZM2 outperforms 76.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 4
Altman-Z 3.64
ROIC/WACC0.73
WACC6.74%
NZM2.DE Yearly LT Debt VS Equity VS FCFNZM2.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 0.72 indicates that NZM2 may have some problems paying its short term obligations.
  • NZM2 has a Current ratio of 0.72. This is amonst the worse of the industry: NZM2 underperforms 91.30% of its industry peers.
  • NZM2 has a Quick Ratio of 0.72. This is a bad value and indicates that NZM2 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of NZM2 (0.44) is worse than 92.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.44
NZM2.DE Yearly Current Assets VS Current LiabilitesNZM2.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NZM2.DE Growth Analysis

3.1 Past

  • NZM2 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.59%, which is quite impressive.
  • The Earnings Per Share has been growing slightly by 6.94% on average over the past years.
  • The Revenue has grown by 8.45% in the past year. This is quite good.
  • Measured over the past years, NZM2 shows a very negative growth in Revenue. The Revenue has been decreasing by -21.57% on average per year.
EPS 1Y (TTM)87.59%
EPS 3Y1.94%
EPS 5Y6.94%
EPS Q2Q%-49.7%
Revenue 1Y (TTM)8.45%
Revenue growth 3Y20.93%
Revenue growth 5Y-21.57%
Sales Q2Q%-50.21%

3.2 Future

  • NZM2 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.42% yearly.
  • NZM2 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.72% yearly.
EPS Next Y8.49%
EPS Next 2Y9.6%
EPS Next 3Y9.8%
EPS Next 5Y8.42%
Revenue Next Year6.98%
Revenue Next 2Y7.11%
Revenue Next 3Y7.08%
Revenue Next 5Y6.72%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NZM2.DE Yearly Revenue VS EstimatesNZM2.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
NZM2.DE Yearly EPS VS EstimatesNZM2.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

2

4. NZM2.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 27.05, NZM2 can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of NZM2 is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Earnings ratio of 24.75, NZM2 is valued at the same level.
  • With a Price/Forward Earnings ratio of 24.94, NZM2 is valued on the expensive side.
  • NZM2's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. NZM2 is more expensive than 60.87% of the companies in the same industry.
  • NZM2 is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 27.05
Fwd PE 24.94
NZM2.DE Price Earnings VS Forward Price EarningsNZM2.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NZM2 indicates a slightly more expensive valuation: NZM2 is more expensive than 60.87% of the companies listed in the same industry.
  • 63.77% of the companies in the same industry are more expensive than NZM2, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 28.09
EV/EBITDA 16.07
NZM2.DE Per share dataNZM2.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20 25

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates NZM2 does not grow enough to justify the current Price/Earnings ratio.
  • NZM2 has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.19
PEG (5Y)3.9
EPS Next 2Y9.6%
EPS Next 3Y9.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. NZM2.DE Dividend Analysis

5.1 Amount

  • NZM2 has a Yearly Dividend Yield of 1.73%.
  • NZM2's Dividend Yield is comparable with the industry average which is at 2.35.
  • NZM2's Dividend Yield is comparable with the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.73%

5.2 History

  • The dividend of NZM2 decreases each year by -30.39%.
Dividend Growth(5Y)-30.39%
Div Incr YearsN/A
Div Non Decr YearsN/A
NZM2.DE Yearly Dividends per shareNZM2.DE Yearly Dividends per shareYearly Dividends per share 2022 2026 1 2 3 4 5

5.3 Sustainability

  • 69.00% of the earnings are spent on dividend by NZM2. This is not a sustainable payout ratio.
DP69%
EPS Next 2Y9.6%
EPS Next 3Y9.8%
NZM2.DE Yearly Income VS Free CF VS DividendNZM2.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
NZM2.DE Dividend Payout.NZM2.DE Dividend Payout, showing the Payout Ratio.NZM2.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

NZM2.DE Fundamentals: All Metrics, Ratios and Statistics

NOVONESIS (NOVOZYMES) B

FRA:NZM2 (3/27/2026, 7:00:00 PM)

50.86

+0.89 (+1.78%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners34.36%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap21.08B
Revenue(TTM)4.16B
Net Income(TTM)583.60M
Analysts73.33
Price Target63.75 (25.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.73%
Yearly Dividend0.86
Dividend Growth(5Y)-30.39%
DP69%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.53%
Min EPS beat(2)-16.62%
Max EPS beat(2)45.68%
EPS beat(4)3
Avg EPS beat(4)12.37%
Min EPS beat(4)-16.62%
Max EPS beat(4)45.68%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.23%
Min Revenue beat(2)-3.15%
Max Revenue beat(2)-1.31%
Revenue beat(4)1
Avg Revenue beat(4)-1.59%
Min Revenue beat(4)-3.15%
Max Revenue beat(4)0.34%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.48%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.31%
EPS NY rev (3m)-0.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-1.13%
Valuation
Industry RankSector Rank
PE 27.05
Fwd PE 24.94
P/S 5.07
P/FCF 28.09
P/OCF 17.26
P/B 1.94
P/tB N/A
EV/EBITDA 16.07
EPS(TTM)1.88
EY3.7%
EPS(NY)2.04
Fwd EY4.01%
FCF(TTM)1.81
FCFY3.56%
OCF(TTM)2.95
OCFY5.79%
SpS10.03
BVpS26.18
TBVpS-0.56
PEG (NY)3.19
PEG (5Y)3.9
Graham Number33.28
Profitability
Industry RankSector Rank
ROA 3.57%
ROE 5.38%
ROCE 6.49%
ROIC 4.92%
ROICexc 5.03%
ROICexgc 30.13%
OM 21.23%
PM (TTM) 14.04%
GM 53.91%
FCFM 18.06%
ROA(3y)5.41%
ROA(5y)8.41%
ROE(3y)9.92%
ROE(5y)16.58%
ROIC(3y)8.21%
ROIC(5y)11.27%
ROICexc(3y)11.78%
ROICexc(5y)17.24%
ROICexgc(3y)28.42%
ROICexgc(5y)33.79%
ROCE(3y)10.82%
ROCE(5y)14.84%
ROICexgc growth 3Y-8.21%
ROICexgc growth 5Y7.08%
ROICexc growth 3Y-41.44%
ROICexc growth 5Y-22.29%
OM growth 3Y-5.01%
OM growth 5Y-3.32%
PM growth 3Y-12.48%
PM growth 5Y-6.99%
GM growth 3Y-0.4%
GM growth 5Y-0.77%
F-Score8
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 4
Debt/EBITDA 0.88
Cap/Depr 78.87%
Cap/Sales 11.32%
Interest Coverage 13.29
Cash Conversion 82.56%
Profit Quality 128.63%
Current Ratio 0.72
Quick Ratio 0.44
Altman-Z 3.64
F-Score8
WACC6.74%
ROIC/WACC0.73
Cap/Depr(3y)95.71%
Cap/Depr(5y)113.86%
Cap/Sales(3y)10.73%
Cap/Sales(5y)11.39%
Profit Quality(3y)137.94%
Profit Quality(5y)106.77%
High Growth Momentum
Growth
EPS 1Y (TTM)87.59%
EPS 3Y1.94%
EPS 5Y6.94%
EPS Q2Q%-49.7%
EPS Next Y8.49%
EPS Next 2Y9.6%
EPS Next 3Y9.8%
EPS Next 5Y8.42%
Revenue 1Y (TTM)8.45%
Revenue growth 3Y20.93%
Revenue growth 5Y-21.57%
Sales Q2Q%-50.21%
Revenue Next Year6.98%
Revenue Next 2Y7.11%
Revenue Next 3Y7.08%
Revenue Next 5Y6.72%
EBIT growth 1Y37.28%
EBIT growth 3Y14.87%
EBIT growth 5Y-24.18%
EBIT Next Year73.55%
EBIT Next 3Y26.96%
EBIT Next 5Y18.46%
FCF growth 1Y13.73%
FCF growth 3Y71.25%
FCF growth 5Y-26.14%
OCF growth 1Y19.77%
OCF growth 3Y31.55%
OCF growth 5Y-22.45%

NOVONESIS (NOVOZYMES) B / NZM2.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NOVONESIS (NOVOZYMES) B (NZM2.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to NZM2.DE.


What is the valuation status for NZM2 stock?

ChartMill assigns a valuation rating of 2 / 10 to NOVONESIS (NOVOZYMES) B (NZM2.DE). This can be considered as Overvalued.


What is the profitability of NZM2 stock?

NOVONESIS (NOVOZYMES) B (NZM2.DE) has a profitability rating of 6 / 10.


What is the earnings growth outlook for NOVONESIS (NOVOZYMES) B?

The Earnings per Share (EPS) of NOVONESIS (NOVOZYMES) B (NZM2.DE) is expected to grow by 8.49% in the next year.


Can you provide the dividend sustainability for NZM2 stock?

The dividend rating of NOVONESIS (NOVOZYMES) B (NZM2.DE) is 2 / 10 and the dividend payout ratio is 69%.